Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)-Reference-Cited by-同舟云学术

Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)

Published:2020-01 Issue:1 Volume:31 Page:72-78
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Holch J.W.^ORCID,Held S.,Stintzing S.,Fischer von Weikersthal L.,Decker T.,Kiani A.,Kaiser F.,Heintges T.,Kahl C.,Kullmann F.,Scheithauer W.,Moehler M.,von Einem J.C.,Michl M.,Heinemann V.

Funder

Pfizer

Merck KGaA

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference16 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial;Stintzing;Lancet Oncol,2016

3. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer;Heinemann;Eur J Cancer,2016

4. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials;Holch;Eur J Cancer,2017

5. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab;Piessevaux;J Clin Oncol,2013

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tectorigenin Inhibits Glycolysis-induced Cell Growth and Proliferation by Modulating LncRNA CCAT2/miR-145 Pathway in Colorectal Cancer;Current Cancer Drug Targets;2024-10

2. Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial;ESMO Open;2024-07

3. Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice;Frontiers in Immunology;2024-04-16

4. Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM;ESMO Open;2024-04

5. Early thrombocytopenia predicts longer time‑to‑treatment discontinuation in trastuzumab emtansine treatment;Oncology Letters;2023-10-23